GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (NAS:ABIO) » Definitions » E10

ABIO (ARCA biopharma) E10 : $-239.29 (As of Jun. 2024)


View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ARCA biopharma's adjusted earnings per share data for the three months ended in Jun. 2024 was $-2.160. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-239.29 for the trailing ten years ended in Jun. 2024.

During the past 3 years, the average E10 Growth Rate was 41.10% per year. During the past 5 years, the average E10 Growth Rate was 40.00% per year. During the past 10 years, the average E10 Growth Rate was 48.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of ARCA biopharma was 62.80% per year. The lowest was 8.90% per year. And the median was 38.50% per year.

As of today (2025-03-15), ARCA biopharma's current stock price is $25.50. ARCA biopharma's E10 for the quarter that ended in Jun. 2024 was $-239.29. ARCA biopharma's Shiller PE Ratio of today is .


ARCA biopharma E10 Historical Data

The historical data trend for ARCA biopharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma E10 Chart

ARCA biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,371.88 -1,370.72 -856.41 -529.89 -280.18

ARCA biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -347.17 -318.54 -280.18 -259.47 -239.29

Competitive Comparison of ARCA biopharma's E10

For the Biotechnology subindustry, ARCA biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARCA biopharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's Shiller PE Ratio falls into.



ARCA biopharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ARCA biopharma's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-2.16/132.5538*132.5538
=-2.160

Current CPI (Jun. 2024) = 132.5538.

ARCA biopharma Quarterly Data

per share eps CPI Adj_EPS
201409 -164.159 100.428 -216.672
201412 -187.919 99.070 -251.433
201503 -196.558 99.621 -261.536
201506 -149.039 100.684 -196.215
201509 -66.959 100.392 -88.411
201512 -60.480 99.792 -80.335
201603 -86.399 100.470 -113.989
201606 -92.879 101.688 -121.071
201609 -110.159 101.861 -143.352
201612 -99.359 101.863 -129.296
201703 -103.679 102.862 -133.606
201706 -127.439 103.349 -163.451
201709 -84.239 104.136 -107.227
201712 -73.439 104.011 -93.592
201803 -43.320 105.290 -54.538
201806 -32.880 106.317 -40.994
201809 -24.720 106.507 -30.765
201812 -23.040 105.998 -28.812
201903 -22.320 107.251 -27.586
201906 -13.680 108.070 -16.779
201909 -9.120 108.329 -11.159
201912 -8.280 108.420 -10.123
202003 -9.960 108.902 -12.123
202006 -8.760 108.767 -10.676
202009 -3.960 109.815 -4.780
202012 -6.441 109.897 -7.769
202103 -3.960 111.754 -4.697
202106 -4.080 114.631 -4.718
202109 -3.960 115.734 -4.536
202112 -4.800 117.630 -5.409
202203 -2.760 121.301 -3.016
202206 -2.640 125.017 -2.799
202209 -1.920 125.227 -2.032
202212 -0.960 125.222 -1.016
202303 -1.080 127.348 -1.124
202306 -1.200 128.729 -1.236
202309 -1.200 129.860 -1.225
202312 -0.960 129.419 -0.983
202403 -1.680 131.776 -1.690
202406 -2.160 132.554 -2.160

Add all the adjusted EPS together and divide 10 will get our e10.


ARCA biopharma  (NAS:ABIO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


ARCA biopharma E10 Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


ARCA biopharma Business Description

Traded in Other Exchanges
N/A
Address
10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Executives
James P Flynn director 41 HARRIS CT, DANVILLE CA 94526
Funicular Funds, Lp 10 percent owner, other: See Footnote 1 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Funicular Fund, Lp other: See Footnote 1 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Jacob Ma-weaver other: See Remarks 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Christopher David Ozeroff officer: S.V.P., General Counsel 8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021
Robert E Conway director C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
C. Jeffrey Dekker officer: Chief Financial Officer 10170 CHURCH RANCH WAY, WESTMINSTER CO 80021
Thomas A Keuer officer: Chief Operating Officer C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021
Brian L. Selby officer: VP, Finance 11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020
Venrock Healthcare Capital Partners Lp 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Scott D Sandell 10 percent owner
David M Mott 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Forest Baskett 10 percent owner
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202